Rocket One's Hoth Therapeutics Subsidiary Plans To End Its Phase 2a Clinical Study Of HT-001 After Interim Efficacy Data; Intends To Seek FDA Feedback For Conducting HT-001 Into Potential Phase 3 Clinical Program
Rocket One Inc. (NASDAQ:RKTO) ("Rocket One" or the "Company") today announced that its biotechnology subsidiary, Hoth Therapeutics, has decided to end its Phase 2a clinical trial of HT-001 early
Hoth Therapeutics is stopping its mid-stage medicine study early. The company thinks the results are good enough to talk with the FDA about the next testing step.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.